<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04509765</url>
  </required_header>
  <id_info>
    <org_study_id>19-00664</org_study_id>
    <nct_id>NCT04509765</nct_id>
  </id_info>
  <brief_title>A Phase II Single-arm Study of Total Body Irradiation With Linac Based VMAT and IGRT</brief_title>
  <official_title>A Phase II Single-Arm Study of Total Body Irradiation With Linac Based Volumetric Modulated Arc Therapy (VMAT) and Image Guided Radiation Therapy (IGRT)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>NYU Langone Health</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>NYU Langone Health</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Single institution study of safety of linac based VMAT TBI for myeloablative treatment in&#xD;
      hematologic malignancies.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Total Body Irradiation (TBI) continues to play an important role in myeloablative and&#xD;
      non-myeloablative conditioning regimens for Allogeneic Stem Cell Transplant (ASCT). When TBI&#xD;
      is used as part of a myeloablative regimen, it is combined with chemotherapy to eradicate&#xD;
      malignant cells, as well as to immunosuppress the host to prevent rejection of donor&#xD;
      hematopoietic progenitor cells (HPC).&#xD;
&#xD;
      This study is a single-institution study to assess the safety of linac based VMAT TBI for&#xD;
      myeablative sreatment in hematologic malignancies.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 22, 2020</start_date>
  <completion_date type="Anticipated">February 2024</completion_date>
  <primary_completion_date type="Anticipated">February 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of patients who achieve excellent coverage while sparing the lung</measure>
    <time_frame>Up to 1 year post-transplant</time_frame>
    <description>Excellent coverage while sparing the lung is quantified by meeting the following dosimetric parameters (all parameters must be met):&#xD;
V100%= &gt;90% (90% of PTV volume getting 100% of the dose).&#xD;
D98&gt;85% (98% of the volume getting at least 85% of the dose).&#xD;
Mean Lung dose &lt;900cGy.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cumulative incidence rate of idiopathic pneumonia syndrome</measure>
    <time_frame>Up to 100 days post-transplant</time_frame>
    <description>Non-infectious pneumonia syndrome is defined by the American Thoracic Society as at least 1 of the following without concurrent infection detected on blood culture, broncoalveolar lavage, lung biopsy or sputum:&#xD;
There must also be the absence of cardiac dysfunction, acute renal failure, or iatrogenic fluid overload as etiology for pulmonary dysfunctionMultilobar infiltrates on chest radiograph or computed tomography (CT);&#xD;
Symptoms and signs of pneumonia including dyspnea, cough, cyanosis, hypoxia or pyrexia;&#xD;
New or increased restrictive patters on pulmonary function testing or increased alveolar to arterial oxygen difference</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Occurrence of acute GVHD, transplant related mortality, or mortality in the first 100 days following transplant</measure>
    <time_frame>100 days post-transplant</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Event Free Survival (EFS)</measure>
    <time_frame>Up to 1 year post-transplant</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients who achieved a mean dose to each kidney (Dmean) &lt; 11Gy</measure>
    <time_frame>Up to 150 days post-transplant</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients who have achieved a maximum dose to 2cc of the entire body (D2cc) &lt; 130% of Rx dose.</measure>
    <time_frame>Up to 150 days post-transplant</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients who have achieved a maximum dose to 0.03cc of OARs &lt; 120% of Rx dose.</measure>
    <time_frame>Up to 150 days post-transplant</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">15</enrollment>
  <condition>Hematologic Malignancy</condition>
  <arm_group>
    <arm_group_label>Patients with Hematologic Malgnancies</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Linac Based VMAT TBI</intervention_name>
    <description>Use of linac based Volumetric Arc Therapy (VMAT) to deliver Total Body Irradiation (TBI). The study intervention is a VMAT based delivery technique using a 6 MV photon beam from a Varian TrueBeam® (Palo Alto, CA) equipped with a Millennium multi-leaf collimation (MLC) system3. TBI will be delivered using a Varian TrueBeam linear accelerator with photon beam VMAT capability. VMAT is a radiation technique combining dynamic photon fluence modulation using multi-leaf collimation (MLC) with gantry rotation to deliver a highly conformal dose distribution with improved target coverage and sparing of organs at risk (OARs).</description>
    <arm_group_label>Patients with Hematologic Malgnancies</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Age ≥ 18&#xD;
&#xD;
          2. Patients undergoing related, unrelated (including cord blood) hematopoietic progenitor&#xD;
             cell (HPC) transplant, in which the protocol requires &gt;12 Gray of TBI, as part of the&#xD;
             conditioning regimen.&#xD;
&#xD;
             a. Conditioning regimens outlined per BMT SOP: CLNTX007: Selection of Conditioning&#xD;
             Regimens for Blood and Marrow Transplantation - ADULTS.&#xD;
&#xD;
          3. Referral from the blood and marrow transplant (BMT) program for full-dose TBI, who&#xD;
             meet inclusion and exclusion criterial per BMT SOPs.&#xD;
&#xD;
               1. BMT program will initiate referral, utilizing Form: 170102, Radiation Oncology&#xD;
                  Consultation.&#xD;
&#xD;
               2. Patients undergo pre-transplant testing, as defined in BMT SOPs:CLNAL002: Related&#xD;
                  (MRD, Haplo) Allogeneic Recipient Evaluation and Management or CLNAL011:&#xD;
                  Unrelated (MUD, MMUD, CBU) Allogeneic Recipient Evaluation and Management, per&#xD;
                  below.&#xD;
&#xD;
             i. BMT SOP's include baseline pulmonary function tests (PFTs). Patient with decreased&#xD;
             FVC, FEV1 and or DLCO (adjusted for hemoglobin) or pulmonary history will have&#xD;
             pulmonary consult, at the discretion of the BMT physician prior to undergoing&#xD;
             myeloablative radiation.&#xD;
&#xD;
        ii. Medical history and physical by BMT provider.&#xD;
&#xD;
        iii. The following laboratory tests (additional testing may be required for positive&#xD;
        results):&#xD;
&#xD;
          -  ABO group and Rh type&#xD;
&#xD;
          -  Red Blood Cell Antibody Screen.&#xD;
&#xD;
          -  HLA typing and confirmatory typing&#xD;
&#xD;
          -  HLA antibody screen, class I and II, performed within 30 days of transplant.&#xD;
&#xD;
          -  Complete blood count (CBC) with differential.&#xD;
&#xD;
          -  Basic metabolic panel, including glucose and to include at a minimum electrolyte&#xD;
             evaluation of potassium, calcium, magnesium, and phosphorus.&#xD;
&#xD;
          -  Blood urea nitrogen (BUN)&#xD;
&#xD;
          -  Creatinine&#xD;
&#xD;
          -  Liver Function Tests including: Total bilirubin, Alkaline phosphatase, Aspartate&#xD;
             aminotransferase (AST), Alanine aminotransferase (ALT), Lactate dehydrogenase (LDH),&#xD;
             Albumin, Total Protein, Urinalysis&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Patient receiving less than 1200 cGy of TBI&#xD;
&#xD;
          2. Previous history of thoracic radiation therapy including previous TBI&#xD;
&#xD;
          3. All premenopausal women will require a urine qualitative pregnancy test to exclude&#xD;
             pregnancy. Pregnant women will be excluded from the study.&#xD;
&#xD;
          4. Prisoners&#xD;
&#xD;
          5. Patient not meeting transplant criteria per BMT physician.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Naamit Gerber, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>NYU Langone Health</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Kelsey Stocker, RN</last_name>
    <phone>646-501-4723</phone>
    <email>kelsey.stocker@nyulangone.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Angelica Husni</last_name>
    <phone>646-501-7869</phone>
    <email>Angelica.Husni@nyulangone.org</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>NYU Langone Health</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10016</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kelsey Stocker</last_name>
      <phone>646-501-4723</phone>
      <email>kelsey.stocker@nyulangone.org</email>
    </contact>
    <contact_backup>
      <last_name>Angelica Husni</last_name>
      <phone>6465017869</phone>
      <email>Angelica.Husni@nyulangone.org</email>
    </contact_backup>
    <investigator>
      <last_name>Naamit Gerber, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>David Barbee, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jose Teruel</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Christine Hitchen</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Martha Malin, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>K. Sunshine Osterman, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Paulina Galavis, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Samir Al-Homsi, MD, MBA</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Mohammad Abdul Hay, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>August 10, 2020</study_first_submitted>
  <study_first_submitted_qc>August 10, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">August 12, 2020</study_first_posted>
  <last_update_submitted>February 2, 2021</last_update_submitted>
  <last_update_submitted_qc>February 2, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 4, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Myeloablative Treatment</keyword>
  <keyword>Total Body Irradiation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hematologic Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Individual participant data that underlie the results reported in this article, after deidentification (text, tables, figures, and appendices) will be shared upon reasonable request.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_time_frame>Data will become available beginning 9 months and ending 36 months following article publication or as required by a condition of awards and agreements supporting the research.</ipd_time_frame>
    <ipd_access_criteria>The investigator who proposed to use the data will have access to the data upon reasonable request. Requests should be directed to naamit.gerber@nyulangone.org. To gain access, data requestors will need to sign a data access agreement.</ipd_access_criteria>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

